Dermatological side‐effects in hepatitis C infected patients under a triple regimen associating pegylated interferon, ribavirin and telaprevir. (3rd September 2014) - Bernardeschi, C.; Valeyrie‐Allanore, L.; Ortonne, N.; Gressier, L.; Wallet‐Faber, N.; Bernard, P.‐H.; Hezode, C.; Duclos‐Vallée, J.‐C.; Samuel, D.; Mallet, V.; Pol, S.; Milpied, B.; et al.